Zobrazeno 1 - 10
of 61
pro vyhledávání: ''
Autor:
Beatriz Castelo, Jacobo Rogado, Paula Jiménez-Fonseca, Eva Martínez de Castro, Raquel Hernández, Oliver Higuera, Alberto Carmona-Bayonas, Ismael Ghanem, María del Mar Muñoz, Caterina Calderon
Publikováno v:
Cancer Investigation. 39:589-596
The aim of this study was to compare physicians' and patients' estimates of risk of relapse and toxicity. A prospective, cross-sectional, multicenter study including 735 patients with cancer and 29 oncologists. Physicians' appraisals of risk of relap
Autor:
Kadir Eser, Pinar Saip, Erdem Cubukcu, Fuat Demirelli, Ozkan Alan, Zuleyha Calikusu, Aykut Bahceci, Ali Alkan, Hacer Demir, Mahmut Büyükşimşek, Cemile Karadeniz, Erhan Gokmen, Naziye Ak, Mehmet Bilici, Altay Aliyev, Turkkan Evrensel, Oznur Bal, Atakan Demir, Özge Keskin, Nilgün Yildirim, Saadettin Kilickap, Semra Paydas, Atike Gökçen Demiray, Kezban Nur Pilanci, Ali Gökyer, Perran Fulden Yumuk, Birol Yildiz, Duygu Ilke Cikman, Ismail Beypinar, Taner Korkmaz, Sinan Yavuz, Burcu Çakar, Erkan Arpaci, Gulsah Seydaoglu, Ferhat Ferhatoglu, Ahmet Z. Sahin, Gulcan Bulut, Serkan Degirmencioglu, Cengiz Karacin, Mutlu Dogan, Havva Yesil Cinkir, Kerem Okutur, Semiha Urvay, Deniz Işik, Melih Simsek, Osman Kostek, Meltem Baykara, Salim Basol Tekin, Deniz Yamac
Publikováno v:
Cancer Investigation. 39:473-481
Aim: The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method: Retrospective analysis of T-DM1 results of human epidermal grow
Publikováno v:
Cancer Investigation. 36:424-430
It is not clear whether sequential chemotherapy can be performed immediately in patients with p-stage I non-small cell lung cancer recurring during a 2-year period of daily oral administration with tegafur-uracil (UFT) as postoperative adjuvant chemo
Autor:
Rami Owera, Howard A. Burris, Mathew John Joseph, Ruth E. Lamar, David R. Spigel, Johanna C. Bendell, Cassie M. Lane, D. S. Thompson, Chris Earwood, William Penley, Todd M. Bauer
Publikováno v:
Cancer Investigation. 34:265-270
AUY922 is an inhibitor of heat shock protein 90 (Hsp90). Hsp90 inhibitors induce kit degradation in preclinical gastrointestinal stromal tumor (GIST) models. This trial was designed to determine the progression-free survival (PFS) of patients with GI
Autor:
Rosaria Barbarino, Alessandra Carosi, Riccardo Santoni, Alessandra Murgia, Gianluca Ingrosso, Michaela Benassi, Pierluigi Bove, Elisabetta Ponti, Luana Di Murro, Emilia Giudice, Daniela di Cristino
Publikováno v:
Cancer Investigation. 32:526-532
We evaluated the clinical impact of a high definition micro-multileaf collimator and a linac-integrated cone-beam computed tomography in 142 patients treated with conformal radiotherapy for localized prostate cancer to a total dose of 76 Gy. Details
Autor:
William T. Barry, Debra Shoemaker, James E. Herndon, Neal Ready, Jeffrey Crawford, Gautam Jha, Lin Gu, Michael J. Kelley
Publikováno v:
Cancer investigation. 35(1)
The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients wh
Autor:
Dana S. Thompson, Dianna Shipley, Charles D. Webb, John D. Hainsworth, William Charles Penley, David M. Waterhouse, F. Anthony Greco
Publikováno v:
Cancer Investigation. 31:323-329
Purpose: To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). Methods: Patients with advanced RCC and ≤1 previous targeted therapy were treated. Results: Maximum tolerated doses were sorafenib 200 mg P
Publikováno v:
Cancer Investigation. 31:177-182
Introduction: This study evaluated objective response and safety for the combination of granulocyte macrophage-colony stimulating factor (GM-CSF), ketoconazole, and mitoxantrone in castration-resistant prostate cancer (CRPC) patients who previously f
Autor:
Jeff Infante, F. Anthony Greco, John D. Hainsworth, Howard A. Burris, David R. Spigel, Suzanne F. Jones, Dana S. Thompson, Habib H. Doss
Publikováno v:
Cancer Investigation. 29:308-312
The role of tyrosine kinase inhibitors (TKIs) in the treatment of advanced malignancies is well established. Imatinib and vatalanib are oral TKIs with different mechanisms of action. This trial sought to establish the safety, tolerability, and maximu
Autor:
D. Randolph Drosick, Mark Mainwaring, Denise A. Yardley, John D. Hainsworth, Mythili Shastry, Michael A. Stipanov, James D. Peyton, Davey B. Daniel
Publikováno v:
Cancer Investigation. 28:865-871
We investigated the feasibility/efficacy of oxaliplatin in combination with trastuzumab as first-/second-line treatment of HER2-positive metastatic breast cancer (MBC). Patients received oxaliplatin/trastuzumab every 21 days and were evaluated every